



Emergent BioSolutions Reports Financial Results for Second Quarter 2008

August 7, 2008

-- Continued delivery of BioThrax(R) doses under current HHS contract drives 88 percent increase in Q2 2008 revenue over Q2 2007 -- Recent acquisitions expand anthrax franchise -- Financial outlook for 2008 is reaffirmed

ROCKVILLE, Md., Aug 07, 2008 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the second quarter ended June 30, 2008.

Total revenues for the second quarter of 2008 grew 88 percent to \$43.5 million from \$23.2 million in 2007, primarily driven by growth in sales of BioThrax(R) (Anthrax Vaccine Adsorbed). Net income for the second quarter of 2008 was \$1.8 million, or \$0.06 per share, in comparison to a net loss of \$5.0 million, or \$0.17 per share, for the comparable period in 2007.

R. Don Elsey, Emergent BioSolutions' chief financial officer, said, "Our financial performance for the second quarter and first half of 2008 reflects significant progress toward attaining our financial goals for the year. We continue to deliver doses of BioThrax for inclusion in the SNS pursuant to our current multi-year contract with the U.S. Government. Not only are we expanding our internal manufacturing and product development infrastructure, we are investing in strategic acquisitions and partnerships that serve to further bolster our product pipeline. Our acquisition of both a human monoclonal antibody as a therapeutic for anthrax infection and an advanced recombinant protective antigen anthrax vaccine during the first half of this year strengthens our anthrax franchise and enables us to offer solutions to the three phases of anthrax infection."

Mr. Elsey continued, "With respect to our proposed acquisition of the assets of Protein Sciences, bringing the transaction to closure is taking longer than expected. FluBlok(R) would be a good opportunity for us to leverage our core expertise in product development, manufacturing and government contracting in pursuit of creating value for our pipeline. We continue to be committed to working toward achieving a positive resolution in the near term. One possible solution may be to restructure the transaction as a merger and to offer additional up front consideration."

Second Quarter 2008 Highlights

The company achieved the following during the second quarter of 2008:

- Acquired rPA 102, an advanced recombinant protective antigen anthrax vaccine candidate;
- Initiated a Phase IIb clinical trial in healthy patients in the U.S. using the company's oral typhoid vaccine candidate; and
- Signed an asset purchase agreement to acquire Protein Sciences' Phase III recombinant flu vaccine candidate, FluBlok(R), and related novel platform technology.

Product Sales

For the second quarter of 2008, product sales increased by \$19.8 million, or 88 percent, to \$42.3 million from \$22.5 million for the comparable period of 2007, primarily due to a 98 percent increase in the number of doses of BioThrax delivered. Product sales for the second quarter of 2008 consisted of BioThrax sales to HHS of \$41.9 million and aggregate international and other sales of \$0.4 million.

For the six month period of 2008, product sales increased by \$35.9 million, or 75 percent, to \$83.8 million from \$48.0 million for the comparable period of 2007, primarily due to an 82 percent increase in the number of doses of BioThrax delivered. Product sales for the six month period of 2008 consisted of BioThrax sales to HHS of \$83.1 million and aggregate international and other sales of \$0.7 million.

Contracts and Grants Revenues

For the second quarter of 2008, contracts and grants revenues increased by \$0.5 million, or 74 percent, to \$1.2 million from \$0.7 million for the comparable period of 2007. Contracts and grants revenues for the second quarter of 2008 consisted of \$0.8 million from the Sanofi Pasteur collaboration related to recognition of deferred revenue associated with the upfront payment received in 2006 as well as development service revenue all in conjunction with the company's meningitis B vaccine candidate, and \$0.4 million from the National Institute of Allergy and Infectious Diseases (NIAID).

For the six month period of 2008, contracts and grants revenues increased by \$0.7 million, or 42 percent, to \$2.4 million from \$1.7 million for the comparable period of 2007. Contracts and grants revenues for the six month period of 2008 consisted of \$1.6 million in recognition of deferred revenue associated with the upfront payment received in 2006 as well as development service revenue from the Sanofi Pasteur collaboration, and \$0.8 million from the NIAID.

Cost of Product Sales

For the second quarter of 2008, cost of product sales increased by \$2.8 million, or 49 percent, to \$8.7 million from \$5.8 million for the comparable period of 2007. For the six month period of 2008, cost of product sales increased by \$5.3 million, or 47 percent, to \$16.7 million from \$11.4 million for the comparable period in 2007. The increase for both the second quarter and six month period of 2008 was primarily due to a 98 percent and 82 percent increase, respectively, in the number of doses of BioThrax delivered, partially offset by decreased costs associated with improved production yield.

Research and Development

For the second quarter of 2008, research and development expenses increased by \$3.9 million, or 29 percent, to \$17.2 million from \$13.3 million for the comparable period of 2007. This increase reflects higher contract service costs and asset and technology acquisition costs, and includes increased expenses of \$2.6 million on product candidates that are categorized in the biodefense segment, \$0.9 million on product candidates

categorized in the commercial segment and \$0.4 million in other research and development expenses, which are in support of technology platforms and central research and development activities.

For the six month period of 2008, research and development expenses decreased by \$0.2 million, or 1 percent, to \$28.7 million from \$28.9 million for the comparable period of 2007. This decrease reflects lower contract service costs, and includes decreased expenses of \$3.2 million on product candidates that are categorized in the biodefense segment, partially offset by increased expenses of \$2.3 million on product candidates categorized in the commercial segment and \$0.7 million in other research and development expenses, which are in support of technology platforms and central research and development activities.

Selling, General and Administrative

For the second quarter of 2008, selling, general and administrative expenses increased by \$2.4 million, or 19 percent, to \$15.0 million from \$12.7 million for the comparable period of 2007. This increase is primarily attributable to an increase of approximately \$2.1 million resulting from the addition of personnel and increased legal and other professional services related to the company's headquarters and staff organization to support operations as a public company and the overall growth of the business, and an increase of \$0.2 million in sales and marketing expenses related to the growth of staff and an increase in selling and marketing activities.

For the six month period of 2008, selling, general and administrative expenses increased by \$3.2 million, or 14 percent, to \$27.1 million from \$23.9 million for the comparable period of 2007. This increase is primarily attributable to an increase of approximately \$2.8 million resulting from the addition of personnel and increased legal and other professional services related to the company's headquarters and staff organization to support operations as a public company and the overall growth of the business, and an increase of \$0.4 million in sales and marketing expenses related to the growth of staff and an increase in selling and marketing activities.

Financial Condition and Liquidity

Cash and cash equivalents at June 30, 2008 was \$84.0 million compared to \$105.7 million at December 31, 2007 and \$92.7 million at March 31, 2008. The net decrease in cash and cash equivalents resulted primarily from net cash used in operating activities and investing activities of \$0.7 million and \$22.5 million, respectively, offset by net cash provided by financing activities of \$1.6 million.

Financial Outlook for 2008

For 2008, the company reaffirms its expectations for full year total revenues of \$180 to \$195 million, but with a revised bias toward the lower end of the range. The company also reaffirms net income of approximately \$20 million.

Conference Call & Webcast

Company management will host a conference call at 9:00 am Eastern on August 7, 2008 to discuss these financial results, recent business developments and the outlook for 2008. The conference call, which will be open to all interested parties, will be webcast and can be accessed from the Investor Relations section of the Company's website at www.emergentbiosolutions.com, under "Investors". Participants can also access the call by dialing 888.680.0892 or 617.213.4858 (international) and providing passcode 19956266.

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration is not mandatory. To take advantage of pre-registration, proceed to the following website: <https://www.theconferencingservice.com/prereg/key.process?key=PF9C6EMLD>.

(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

A replay of the conference call will be available approximately one hour following the conclusion of the call through August 21, by dialing 888/286-8010 or 617/801-6888 and passcode 58119499. The webcast will be archived on the company's website, www.emergentbiosolutions.com, under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission--to protect life. Emergent develops, manufactures and commercializes vaccines and biotherapeutics that assist the body's immune system to prevent or treat disease. Emergent's products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. The company's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including our expected revenue growth and net earnings for 2008, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including our ability to obtain new BioThrax(R) sales contracts with the U.S. government; our plans for future sales of BioThrax; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company's current report on Form 10-Q for the quarter ended March 31, 2008 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this

press release.

Financial Statements Follow

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)

	Three Months Ended June 30,	
	2008	2007
	(unaudited)	
Revenues:		
Product sales	\$42,326	\$ 22,518
Contracts and grants	1,159	668
Total revenues	43,485	23,186
Operating expense:		
Cost of product sales	8,682	5,842
Research and development	17,206	13,342
Selling, general and administrative	15,039	12,659
Income (loss) from operations	2,558	(8,657)
Other income (expense):		
Interest income	457	599
Interest expense	(5)	(21)
Other income (expense), net	198	1
Total other income (expense)	650	579
Income (loss) before provision for (benefit from) income taxes	3,208	(8,078)
Provision for (benefit from) income taxes	1,393	(3,117)
Net income (loss)	\$ 1,815	\$(4,961)
Earnings (loss) per share -- basic	\$ 0.06	\$ (0.17)
Earnings (loss) per share -- diluted	\$ 0.06	\$ (0.17)
Weighted-average number of shares -- basic	29,764	28,599
Weighted-average number of shares -- diluted	30,045	28,599

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)

	Six Months Ended June 30,	
	2008	2007
	(unaudited)	
Revenues:		
Product sales	\$83,830	\$ 47,964
Contracts and grants	2,375	1,670

Total revenues	86,205	49,634
Operating expense:		
Cost of product sales	16,692	11,358
Research and development	28,681	28,912
Selling, general and administrative	27,097	23,851
	-----	-----
Income (loss) from operations	13,735	(14,487)
Other income (expense):		
Interest income	1,122	1,473
Interest expense	(6)	(47)
Other income (expense), net	184	178
	-----	-----
Total other income (expense)	1,300	1,604
Income (loss) before provision for (benefit from) income taxes	15,035	(12,883)
Provision for (benefit from) income taxes	6,194	(5,233)
	-----	-----
Net income (loss)	\$ 8,841	\$ (7,650)
	-----	-----
Earnings (loss) per share -- basic	\$ 0.30	\$ (0.27)
Earnings (loss) per share -- diluted	\$ 0.30	\$ (0.27)
Weighted-average number of shares -- basic	29,757	28,234
Weighted-average number of shares -- diluted	29,930	28,234

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and per share data)

	June 30,	December
	2008	31, 2007
	-----	-----
	(unaudited)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 84,007	\$105,730
Accounts receivable	22,451	18,817
Inventories	18,879	16,897
Note receivable	10,000	-
Prepaid expenses and other current assets	4,691	2,866
	-----	-----
Total current assets	140,028	144,310
	-----	-----
Property, plant and equipment, net	118,365	110,218
Deferred tax assets, net	12,962	12,397
Restricted cash	5,200	5,200
Other assets	1,364	1,383
	-----	-----
Total assets	\$277,919	\$273,508
	-----	-----
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 19,933	\$ 20,257
Accrued expenses and other current liabilities	1,267	1,778
Accrued compensation	7,315	9,502
Indebtedness under line of credit	15,000	11,832

Long-term indebtedness, current portion	3,707	3,514
Income taxes payable	4,108	7,665
Deferred tax liabilities, net	139	211
Deferred revenue, current portion	901	902
	-----	-----
Total current liabilities	52,370	55,661
	-----	-----
Long-term indebtedness, net of current portion	40,605	42,588
Deferred revenue, net of current portion	2,180	2,473
Other liabilities	1,649	1,627
	-----	-----
Total liabilities	96,804	102,349
	-----	-----
Commitments and contingencies	-	-
Stockholders' equity:		
Preferred Stock \$0.001 par value; 15,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2008 and December 31, 2007	-	-
Common Stock, \$0.001 par value; 100,000,000 shares authorized; 29,807,225 and 29,750,237 shares issued and outstanding at June 30, 2008 and December 31, 2007, respectively	30	30
Additional paid-in capital	103,134	101,933
Accumulated other comprehensive loss	(1,215)	(1,130)
Retained earnings	79,166	70,326
	-----	-----
Total stockholders' equity	181,115	171,159
	-----	-----
Total liabilities and stockholders' equity	\$277,919	\$273,508
	-----	-----

Emergent BioSolutions Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)

	Six Months Ended June 30,	
	2008	2007
	-----	-----
	(unaudited)	
Cash flows from operating activities:		
Net income (loss)	\$ 8,841	\$ (7,650)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Stock-based compensation expense	986	1,160
Depreciation and amortization	2,262	2,332
Deferred income taxes	(637)	9,297
Gain on disposal of property and equipment	(183)	-
Excess tax benefits from stock-based compensation	-	(6,708)
Changes in operating assets and liabilities:		
Accounts receivable	(3,634)	23,934
Inventories	(1,982)	(4,164)
Income taxes	(3,557)	(27,621)
Prepaid expenses and other assets	(1,806)	(1,023)
Accounts payable	1,993	(1,613)
Accrued expenses and other liabilities	(489)	(1,271)
Accrued compensation	(2,187)	420
Deferred revenue	(294)	(680)
	-----	-----

Net cash used in operating activities	(687)	(13,587)
	-----	-----
Cash flows from investing activities:		
Purchases of property, plant and equipment	(12,543)	(27,343)
Issuance of note receivable	(10,000)	-
	-----	-----
Net cash used in investing activities	(22,543)	(27,343)
	-----	-----
Cash flows from financing activities:		
Proceeds from borrowings on long term indebtedness and line of credit	30,000	-
Issuance of common stock subject to exercise of stock options	214	2,419
Principal payments on long term indebtedness and line of credit	(28,622)	(10,154)
Excess tax benefits from stock-based compensation	-	6,708
	-----	-----
Net cash provided by (used in) financing activities	1,592	(1,027)
	-----	-----
Effect of exchange rate changes on cash and cash equivalents	(85)	(481)
	-----	-----
Net decrease in cash and cash equivalents	(21,723)	(42,438)
Cash and cash equivalents at beginning of period	105,730	76,418
	-----	-----
Cash and cash equivalents at end of period	\$ 84,007	\$ 33,980
	-----	-----

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

Investors:

Robert G. Burrows, 301-795-1877

Vice President, Investor Relations

BurrowsR@ebsi.com

or

Media:

Tracey Schmitt, 301-795-1800

Director, Corporate Communications

SchmittT@ebsi.com